Breaking News: Medtronic TAVR Low-Risk Clinical Trial Results Released!

https://www.Heart-Valve-Surgery.com - New four-year results from the Medtronic Low-Risk TAVR Clinical Trial have been released. In this video, Dr. Michael Reardon, the national surgical director of the TAVR clinical trial, shares the important outcomes of this research study evaluating the safety-and-effectiveness of transcatheter aortic valve replacement (TAVR) for low-risk patients with severe aortic stenosis. Key questions answered by Dr. Reardon include: 1. Why should heart valve patients be interested in the results of this transcatheter aortic valve replacement (TAVR) clinical trial? 2. What were the four-year outcomes from the Medtronic Evolut Low-Risk TAVR clinical trial? 3. How does the structural deterioration of a Medtronic TAVR compare to a surgical bioprosthetic valve replacement? 4. Are hemodynamics (blood flow) better for a Medtronic TAVR or a surgical valve replacement four years after implant? 5. What are the differences in mortality and disabling stroke for the Medtronic Evolut TAVR in low-risk patients compared to surgical heart valve replacements? 6. Why is this clinical trial important for the lifetime management of heart valve disease? To learn more about about TAVR for aortic stenosis patients, please visit https://tavr.heart-valve-surgery.com/....